₹2,000 Monthly SIP in Nippon India Pharma Fund-Growth Plan for 15 Years
If you had started a ₹2,000/month SIP on 18 Aug 2011 and never stopped — through every crash and rally — here is exactly what happened, using Nippon India Pharma Fund-Growth Plan's actual NAV for all 181 installments.
You invested
₹3,62,000
181 installments
Value today
₹14,53,479
18 Aug 2026
Absolute gain
+₹10,91,479
+301.5%
XIRR (annualised)
16.8%
money-weighted
The journey, month by month
Worst fall on the way
-20.7%
Deepest drop from peak. This is what you had to sit through.
Corrections survived
7
Falls of 10%+ during the period. Every one recovered.
Same SIP in a fixed deposit
₹6,73,665
Modelled at historical FD rates. The fund beat FD by ₹7,79,814.
Year-by-year progress
| Year | Invested | Value | Overall gain |
|---|---|---|---|
| Year 1 (21 Aug 2012) | ₹26,000 | ₹29,361 | +12.9% |
| Year 2 (19 Aug 2013) | ₹50,000 | ₹57,139 | +14.3% |
| Year 3 (18 Aug 2014) | ₹74,000 | ₹1,15,564 | +56.2% |
| Year 4 (18 Aug 2015) | ₹98,000 | ₹1,94,162 | +98.1% |
| Year 5 (18 Aug 2016) | ₹1,22,000 | ₹2,05,825 | +68.7% |
| Year 6 (18 Aug 2017) | ₹1,46,000 | ₹1,99,063 | +36.3% |
| Year 7 (20 Aug 2018) | ₹1,70,000 | ₹2,81,827 | +65.8% |
| Year 8 (19 Aug 2019) | ₹1,94,000 | ₹2,73,359 | +40.9% |
| Year 9 (18 Aug 2020) | ₹2,18,000 | ₹4,72,805 | +116.9% |
| Year 10 (18 Aug 2021) | ₹2,42,000 | ₹6,86,362 | +183.6% |
| Year 11 (18 Aug 2022) | ₹2,66,000 | ₹6,45,190 | +142.6% |
| Year 12 (18 Aug 2023) | ₹2,90,000 | ₹8,28,695 | +185.8% |
| Year 13 (19 Aug 2024) | ₹3,14,000 | ₹12,20,111 | +288.6% |
| Year 14 (18 Aug 2025) | ₹3,38,000 | ₹13,02,789 | +285.4% |
| Year 15 (18 Aug 2026) | ₹3,62,000 | ₹14,53,479 | +301.5% |
Best year of the journey: Year 9 (+59% market move) · Toughest year: Year 6 (-13.4%)
Wealth Time Machine
Watch this exact journey as a 60-second cinematic replay
Every crash headline, every recovery — with your money in it.
Try a different amount
Try a different duration
Past performance does not guarantee future returns. This page shows the historical result of the stated SIP using Nippon India Pharma Fund-Growth Plan's published NAV (source: AMFI) between 18 Aug 2011 and 18 Aug 2026; it is educational research, not investment advice. FD comparison is modelled at historical average FD rates. Mutual fund investments are subject to market risks.